Phase 3 clinical trials of the vaccine was an event-driven analysis of 130 symptomatic COVID-19 cases, reported at least two weeks after the second dose, conducted at 25 sites across India. Covaxin 77.8% Effective Against Covid, Works 65.2% on Delta: Bharat Biotech in Final Phase 3 Trial Analysis
Phase 3 clinical trials of the vaccine was an event-driven analysis of 130 symptomatic COVID-19 cases, reported at least two weeks after the second dose, conducted at 25 sites across India. Covaxin 77.8% Effective Against Covid, Works 65.2% on Delta: Bharat Biotech in Final Phase 3 Trial Analysis
No comments:
Post a Comment